Our laboratory studies the pathogenesis of myeloproliferative neoplasm (MPN), a chronic hematologic malignancy characterized by the somatic acquisition of a mutation in either JAK2 (JAK2V617F) or calreticulin in a hematopoietic stem cell. This mutant clone expands producing excessive numbers of mature myeloid cells. The clinical consequences of MPN are elevated peripheral blood counts, thrombosis, enlarged spleen, debilitating fatigue, excessive inflammation, and transformation to acute leukemia. Our specific focus is identifying the role of inflammation in MPN disease initiation.
Sprague Hall 126